Plain-English translation of NCT06596772 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Phase 3 — Testing in thousands of people, comparing the treatment against what doctors currently use. This is the last big step before approval.
This trial is testing whether a new medication called MB04 works just as well as Enbrel (a well-established treatment) for rheumatoid arthritis. Both are injectable medications given weekly under the skin. The study will follow about 458 people to compare how effective these treatments are, how safe they are, and how your body responds to each one.
Rheumatoid arthritis is a serious condition that can cause joint damage and disability. While Enbrel is an effective treatment, researchers want to know if this new medication can offer patients another reliable option that works just as well, potentially giving people more choices for managing their disease.
You likely qualify if…
You likely don't qualify if…
You would visit the clinic for screening tests within 4 weeks before starting. Then you'd be randomly assigned to receive either the new medication or the established treatment, giving yourself an injection once a week for 24 weeks. After that, you'll continue treatment for another 12 weeks (until week 36), with possible reassignment of which medication you receive. You'll have regular clinic visits to check how you're doing, and even after you stop the medication, you'll have a 4-week follow-up period for safety monitoring.
AI-generated summary from trial data · Jun 11, 2026 · Not medical advice
Bulgaria